

Theme: Evidence for guideline development

Group A – questions and notes

Workshop 1: 13:00 – 14:00

What measures/numbers/data/evidence are needed for guideline development?

How should these be studied?

Who is responsible for studying and communicating the different outcome measures?

Theme: Financing and reimbursement

Group A – questions and notes

Workshop 2: 14:30 – 15:30

Can you think of a reimbursement structure for a panel of pharmacogenetic-genes? What are prerequisites?

Who should be able/be responsible for requesting pharmacogenetic tests? And when/under what circumstances?

How can clear and functional arrangements about reimbursement of pharmacogenetic tests be made?

Theme: Roles and responsibilities of health care providers

Group B – questions and notes

Workshop 1: 13:00 – 14:00

How could consensus be reached about the roles and responsibilities concerning pharmacogenetic care of direct health care providers.

How can we realize clear definition of the role of e.g. the clinical chemists and the patient?

What agreements should be made about roles and responsibilities?

Expertmeeting 13 februari 2017: "Personalized medicine: eligible or not?"
About eligibility of pharmacogenetics for primary care

Who is responsible for facilitating these agreements?

Theme: Registering and exchanging patient data for health care providers

Group B – questions and notes

Workshop 2: 14:30 – 15:30

What are prerequisites for a user friendly registration and exchange system?

What data should be registered and exchanged? Between whom?

What are risks of this data registration and exchange?

Expertmeeting 13 februari 2017: "Personalized medicine: eligible or not?"
About eligibility of pharmacogenetics for primary care

How can we achieve safe registration and exchange?

Who is responsible for development and monitoring of this user friendly registration and exchange system?